Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

NCT02857920 is registered in ClinicalTrials.gov with Fuda Cancer Hospital, Guangzhou as lead sponsor.

NCT NCT02857920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02857920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Lead sponsor
Fuda Cancer Hospital, Guangzhou
Phase
Phase 1/2
Overall status
Completed
Start date
August 1, 2016
Completion date
August 1, 2019
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumour